KIT and acute myeloid leukemia: As a result, dasatinib may also have a role to play in diseases associated with KIT activation loop mutations such as systemic mastiocytosis, acute myelogenous leukaemia (AML), seminoma, gastrointestinal stromal tumours and anal melanomas (Schittenhelm et al., 2006; Antonescu et al., 2007).